expresspharmaOctober 26, 2020
Tag: Arixa Pharma , Pfizer , ARX-1796 , avibactam
Arixa Pharmaceuticals, a company developing next-generation oral antibiotics for drug-resistant Gram-negative infections announced that Pfizer’s Hospital Business has agreed to acquire Arixa.
Arixa’s lead compound, ARX-1796, is an oral prodrug of avibactam, a beta lactamase inhibitor (BLI) that was FDA-approved in 2015 as part of Avycaz (sold by Pfizer as Zaficefta outside the US), an intravenous-only combination with ceftazidime for the treatment of a number of indications caused by Gram-negative pathogens.
Dr Eric M Gordon, Arixa Co-Founder and CSO, led a team to address the challenge of creating a viable prodrug of avibactam with now-patented chemistry. As a result of Arixa’s now patented chemistry, the prodrug of avibactam was 60-80 per cent absorbed when administered orally to humans in a Phase 1 clinical trial, releasing the FDA-approved avibactam molecule in the bloodstream. In contrast, ~7 per cent of the intravenous compound is absorbed orally. Combined with an antibiotic such as ceftibuten, Arixa’s ARX-1796, if approved, opens the way for orally-available avibactam to be part of a next-generation, oral antibiotic combination for resistant urinary tract and other infections.
Financial terms of this acquisition were not disclosed.
Four Oaks Partners advised Arixa in connection with this transaction.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: